Back to speakers

Geoffrey DUSHEIKO

UK


PHC's participations

10th PHC – 2017

Monday, January 30th 2017

Impact of therapy on the QOL

LUNCH WORKSHOPS - 3-DAAs treatment of patient with HIV-HCV co-infection

6th PHC – 2013

Tuesday, January 15th 2013

Why do I treat my patient with pegylated IFN? -

Interactive Luncheons - Room 4 (chairman)

5th PHC – 2012

Monday, January 30th 2012

Triple therapy today. Phase III results in G1 relapsers and non responders (chairman)

4th PHC – 2011

Tuesday, January 18th 2011

HBeAg-negative chronic hepatitis B (chairman)

3rd PHC – 2009

Tuesday, January 20th 2009

HBeAg-positive chronic hepatitis B (chairman)

2nd PHC – 2007

Tuesday, January 23rd 2007

Why do I treat my patients with nucleos(t)ide analogues ? -

1st PHC – 2004

Saturday, September 11th 2004

Treatment of HBeAg-Positive Chronic Hepatitis B with Nucleoside/Nucleotide Analogs (chairman) -

DAY 1 – Friday, August 28

Friday, August 28th 2015

Antiviral treatment in HCV cirrhotic patients on waiting list (chairman) -

Saturday, August 29th 2015

Hepatitis C: new challenges in the era of DAAs (chairman)

10th PHC – 2017

Monday, January 30th 2017

Impact of therapy on the QOL

LUNCH WORKSHOPS - 3-DAAs treatment of patient with HIV-HCV co-infection -